

## Board Meeting in Public Monday, 18 May 2026

<b>Title of Paper</b>	Governance Update	<b>Agenda No.</b>	5.1
<b>Nature of Paper</b>	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
<b>Author(s)</b>	Silena Dominy, Company Secretary		
<b>Lead Executive</b>	Helen Gillan, Director of Quality and Governance		
<b>Non-Executive Director Sponsor</b>	Peter Wyman, Chair		
<b>Presenter(s) at Meeting</b>	Silena Dominy, Company Secretary		
<b>Presented for</b>	<input checked="" type="checkbox"/> Approval <input type="checkbox"/> Assurance	<input checked="" type="checkbox"/> Information <input type="checkbox"/> Update	
<b>Is there a plan to communicate this to the organisation?</b>	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Yet to be determined
<b>Executive Summary</b>			
This report provides the Board with an update on corporate governance matters in NHS Blood and Transplant (NHSBT).			
<b>Previously Considered by</b>			
N/A			
<b>Recommendation</b>			
The Board is asked to note the report and approve the reappointment of Nicola Yates as Non-Executive Director for a further term of one-year with effect from 17 July 2026.			
<b>Risk(s) identified (Link to Board Assurance Framework Risks)</b>			
BAF P11 Corporate Governance			
<b>Strategic Objective(s) this paper relates to:</b>			
<input checked="" type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input type="checkbox"/> Drive innovation <input checked="" type="checkbox"/> Modernise our operations <input type="checkbox"/> Grow and diversify our donor base			
<b>Appendices:</b>			

## 1. Background

This report provides the Board with an update on Corporate Governance matters in NHSBT.

## 2. Board Level Policies

This meeting presents the following Board Level Policies for approval:

- BLP5 – Risk Management Policy (agenda item 4.3)

In addition, the Standing Orders, Scheme of Delegation and Standing Financial Instructions have been reviewed and are presented under agenda item 4.2 for approval.

## 3. Board Appointments

### Department of Health and Social Care Appointments

Following the completion of pre-appointment and Fit and Proper Person checks, the Department of Health and Social Care have confirmed that:

- Ian Murphy has been re-appointed as a Non-Executive Director of NHSBT and Chair of the NHSBT Audit, Risk and Governance Committee for 3 years from 1 March 2027, being the day following the expiry of his current term.
- Penny McIntyre has been re-appointed as a Non-Executive Director of NHSBT for 3 years from 1 March 2027, being the day following the expiry of her current term.
- Lorna Marson has tendered her resignation as Non-Executive Director of NHSBT and will be leaving her role on 30 June 2026.

### NHSBT Board Appointments

Nicola Yates' current term of office as Associate Non-Executive Director is due to expire on 16 July 2026. It is proposed that Nicola be reappointed by the Board for a further one-year term.

Rommel Ramanan has been appointed Chief Medical Officer and commences this role on 1 July 2026, transitioning fully to the role on 1 August 2026. In line with statute Rommel becomes a voting member of the Board at that time.

Michael Burton has been appointed Interim Director of Clinical Services with effect from 1 May 2026 for a period of six months and becomes a non-voting member of the Board for that period.

## 4. Stakeholder Engagement

Information in relation to engagements of the Chair and Interim Chief Executive with stakeholders and DHSC since the last meeting is included in the Review Room for this meeting.